logo
How a toxic seaweed choking Caribbean beaches could become a valuable resource

How a toxic seaweed choking Caribbean beaches could become a valuable resource

Yahoo15-05-2025
Each year, between March and October, large amounts of brown seaweed called sargassum wash up on the shores of Caribbean islands – choking beaches, damaging marine life and threatening tourism and public health. But a number of local entrepreneurs are hoping the seaweed could create an economic opportunity.
From the coast of west Africa to the Caribbean Sea and the Gulf of Mexico, climate change is warming the temperature of the ocean. Seas are also becoming more acidic as water absorbs carbon dioxide. This all results in more intense growth of sargassum in the tropical Atlantic.
Small Caribbean nations are among the hardest hit. With 20 million tonnes of this seaweed washing up on the beaches in 2024, sargassum is fuelling an economic and public health crisis.
The piles of noxious seaweed on the Caribbean islands' white sandy beaches are putting off visitors to these islands and probably dampening tourism revenues.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
The fishing sector is also suffering, with blooms of seaweed getting caught up in fishing nets, often ripping them due to the weight of the seaweed. This makes it hard for fishers to catch fish and make a living.
The sheer volume of sargassum left to decompose on land produces toxic fumes that have forced people on islands like Guadeloupe to leave their homes. These toxic fumes have been linked to serious health issues including respiratory infections, sleep apnoea and even preeclampsia (high blood pressure during pregnancy).
The sargassum problem is just one of many slow-onset events that are being exacerbated by climate change. But gradual changes get much less attention or resources to address the consequences than, say, alarming wildfires or flash floods.
Slow-onset events are also much harder to quantify than climate-change-induced extreme weather, such as worsening hurricanes or floods. Our team at ODI Global, a thinktank, recently published a study that estimated the cost of these at US$2,000 (£1,500) per person. Calculating the tourism lost each year due to seaweed inundation is trickier.
Read more:
Despite these challenges, through small-scale, locally developed solutions, as well as government policies that support small businesses including helping them access climate finance, entrepreneurs can find sustainable solutions to help their populations thrive in an era of climate change.
Legena Henry, a lecturer at the University of the West Indies in Barbados, uses sargassum to produce a biofuel that can power cars. Johanan Dujon, the founder and chief executive of St. Lucia-based Algas Organics sells plant tonics made from sargassum and is trialling methods to convert sargassum into paper.
Meanwhile, other innovations are helping to minimise the impacts of sargassum in the region.
Andrés León, founder of SOS Carbon, a spin-off organisation from the mechanical engineering department at the Massachusetts Institute of Technology, has designed a boat-based harvester to collect sargassum at sea to stop it from beaching and causing damage onshore.
Some islands, such as Jamaica, are using early warning systems, typically used to predict hurricanes, to predict the ocean currents that might bring a bumper arrival of the seaweed to their shores. This could give fishers up to 30 days notice of just how bad the inundation will be.
But while small businesses are emerging, turning them into larger enterprises across the region remains difficult. As usual, small island nations struggle to get funding because investors think the projects are too small and won't make enough money.
As Legena Henry recently told us on the Small Island Big Picture podcast, spending a few million dollars (as opposed to a few hundred million dollars) can feel administratively cumbersome for funders as they often have limited administrative capacity and large sums of money to manage.
Another issue is ensuring the benefits from any sargassum solutions flow into the affected Caribbean islands to support local growth and economic development.
Several opportunities exist for small island nations to generate some income from sargassum. They could, for example, sell licences to permit companies to harvest sargassum within their exclusive economic zones, which can stretch around many islands for hundreds of nautical miles.
They can also sell licences to businesses trialling or operating new sargassum technologies within their exclusive economic zones — for example, SOS Carbon has a patent pending for technology designed to sink sargassum to the seabed to store carbon.
Will sargassum continue to be a nuisance, or could it be an important renewable natural resource? It's not yet clear.
Ideally, as with other renewable natural resources in developing countries, small island nations that own the sargassum need to find ways to extract a fair share of the value from that ownership, as well as selling to external companies that come in, remove it and profit from it.
With tax incentives and low-cost finance for domestic innovators, small islands can manage and sell sargassum and then use the proceeds to develop climate resilience measures.
Get a weekly roundup in your inbox instead. Every Wednesday, The Conversation's environment editor writes Imagine, a short email that goes a little deeper into just one climate issue. Join the 45,000+ readers who've subscribed so far.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Emma Tompkins received funding for work on sargassum from the Economic and Social Research Council GCRF (Grant number: ES/T002964/1)
Emily Wilkinson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The US May Have Already Lost the AI Race to China Due to a Key Weakness
The US May Have Already Lost the AI Race to China Due to a Key Weakness

Yahoo

timean hour ago

  • Yahoo

The US May Have Already Lost the AI Race to China Due to a Key Weakness

You might have heard of an "AI race" heating up between the US and China, a bitter rivalry between two global adversaries that could shape the direction of world history. At least, that's how some in the US feel. While China has repeatedly tried to establish a geopolitical friendship with the richest nation in the world, officials and pundits in the US have doubled down, reframing artificial intelligence as the 21st century's nuclear bomb. In the meantime, China may have gotten a massive lead — by actively investing in its power grid, while the United States' is quickly running out of capacity to power immensely power-hungry AI models. As Fortune reports, Americans who've had a look at China's technological development firsthand found that the two country's aren't even in the same league, given China's next-level power grid. "Energy is considered a solved problem," wrote Rui Ma, editor of the US publication Tech Buzz China. "Everywhere we went, people treated energy availability as a given," she continued. "This is a stark contrast to the US, where AI growth is increasingly tied to debates over data center power consumption and grid limitations." AI is a notoriously energy-intensive technology. The data centers powering large language models like ChatGPT are immense labyrinths of computer chips, which suck down resources like power and water in order to keep up with demand. As Fortune notes, this effectively makes electricity the key bottleneck for expanding AI infrastructure. That's caused some critical shortages in the US. Short on energy and hopped up on fantasies of an arms race, American companies are resorting to all kinds of bizarre strategies to get their juice. Elon Musk's xAI, for example, is running 35 portable methane gas generators in the parking lot of one of its main datacenters in Memphis, encircling nearby communities in a cloud of noxious smog. China has no such problems. In 2024, China was responsible for nearly 65 percent of the world's renewable energy construction, installing so many solar panels and wind turbines that it caused the country's CO2 emissions to drop for the first time — despite record-high demands for energy. Whether or not the US can catch up remains to be seen. President Donald Trump previously made an off-the-cuff remark about attaching coal power plants to data centers directly. It's an unfortunate conundrum in an age when energy demand in the US has never been higher. In the meantime, China keeps chugging along, seemingly unperturbed by any energy bottlenecks — and the Trump administration's posturing. More on AI: AI Datacenters Are Raising Nearby Residents' Electric Bills Solve the daily Crossword

1 Stock Down 40% This Year to Buy and Hold
1 Stock Down 40% This Year to Buy and Hold

Yahoo

timean hour ago

  • Yahoo

1 Stock Down 40% This Year to Buy and Hold

Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio

US suspends visas for Gazans after far-right influencer posts
US suspends visas for Gazans after far-right influencer posts

Yahoo

time2 hours ago

  • Yahoo

US suspends visas for Gazans after far-right influencer posts

The US government said Saturday it is suspending visitor visas for Gazans after a far-right influencer with the ear of President Donald Trump complained that wounded Palestinians had been allowed to seek medical treatment in the United States. The announcement came one day after a series of furious social media posts by Laura Loomer, who is known for promoting racist conspiracy theories and claiming that the 9/11 terrorist attacks were an inside job. "All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days," the State Department, which is led by Marco Rubio, wrote on X. In a series of posts on X Friday, Loomer called on the State Department to stop giving visas to Palestinians from Gaza who she said were "pro-HAMAS... affiliated with the Muslim Brotherhood and funded by Qatar," without providing evidence. Loomer's target was the US-based charity HEAL Palestine, which said last week it had helped 11 critically wounded Gazan children -- as well as their caregivers and siblings -- arrive safely in the US for medical treatment. It was "the largest single medical evacuation of injured children from Gaza to the US," the charity said on its website. - 'Dangerous and inhumane' - "Truly unacceptable," Loomer wrote in another X post. "Someone needs to be fired at @StateDept when @marcorubio figures out who approved the visas." "Qatar transported these GAZANS into the US via @qatarairways," she said. Qatar is "literally flooding our country with jihadis," she added. Loomer said she had spoken to the staff of Republican Tom Cotton, who chairs the Senate intelligence committee, adding that they were "also looking into how these GAZANS got visas to come into the US." Republican Congressman Randy Fine explicitly commended Loomer after the visa change was announced, in a sign of her sway over some US policy. "Massive credit needs to be given to @LauraLoomer for uncovering this and making me and other officials aware. Well done, Laura," Fine wrote on X. The Palestine Children's Relief Fund, a US-based charity, called on the Trump administration to "reverse this dangerous and inhumane decision." Over the last 30 years the charity has evacuated thousands of Palestinian children to the US for medical care, it said a statement. "Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza." Though Loomer holds no official position, she wields significant power, and is reported to have successfully pushed for the dismissal of several senior US security officials she deemed disloyal to Trump. In July, Loomer took aim at a job offer made to a highly qualified Biden-era official for a prestigious position at the West Point military academy. The Pentagon rescinded the offer one day later. Trump also fired the head of the highly sensitive National Security Agency, Timothy Haugh, and his deputy Wendy Noble in April at the apparent urging of Loomer, after she met with the president at the White House. "No other content creator or journalist has gotten as many Biden holdovers fired from the Trump admin!" Loomer posted on X Saturday. nr/dl/sla Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store